• Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami
• He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience
• Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success of this recent study
• Mydecine is also set to support Dr. Johnson’s concurrent NIDA grant-funded study through the provision of MYCO-001 for research

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), back in September 2021, announced its seamless phase 2/3 smoking cessation clinical trial that will launch in early 2022. The study, which will be led by Johns Hopkins University’s (“JHU”) Dr. Matthew Johnson, will evaluate the administration of MYCO-001, a 99% pure version of psilocybin, with a structured smoking cessation treatment program in nicotine-dependent individuals (https://ibn.fm/cKxuV). This study builds on similar research initiated by JKU back in 2014, under the leadership of Dr. Johnson, a world-renowned psychedelic drug researcher. This preliminary study showed that 80% of the subjects achieved abstinence at six months following 2-4 oral doses of psilocybin, coupled with extensive cognitive behavioral therapy (“CBT”). It also builds on an ongoing 100-subject randomized trial for which Dr. Johnson presented the interim results at this year’s Psychedelic Medicine Business Event: Wonderland in Miami. Scheduled for November 8-9, 2021, this event was deemed the largest psychedelic medicine business event ever. It covered various topics surrounding the psychedelics industry, including the path to federal acceptance, AI-driven psychedelic drug discovery, precision medicine and psychedelics, and the future of psychedelics. In addition, Dr. Johnson covered psilocybin for tobacco smoking cessation, mainly covering the findings from his research thus far (https://ibn.fm/R950g). Dr. Johnson’s study involved 100 patients considered treatment-resistant smokers and span across 12 months. These participants were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. However, the study involved only one psilocybin session. Dr. Johnson noted that after 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent. This positive data played an integral role in ROTH Capital’s report published on November 16th reiterating Mydecine’s Buy rating and C$3/share 12-month price target following the release of their 3Q21 results. The participants in the study appreciated Dr. Johnson’s work, citing psilocybin’s benefits and how life-changing the entire experience was. “Primarily, I would say it made me understand that my identity is this construct,” one noted. “Seeing that which happened during the psilocybin experiences and being reminded of, and understanding, life as an unspeakably marvelous adventure of existence,” reckoned another. Dr. Johnson is currently leading another separate study, funded by the National Institute on Drug Abuse (“NIDA”). This marks the first time in over 50 years that the United States government has funded a study of a psychedelic compound for therapeutics. Mydecine will supply MYCO-001 for this study and is excited to be part of Dr. Johnson’s research. “We are excited to support Dr. Johnson and his team in this concurrently running study, which we believe will add a significant benefit to support our 2/3 seamless design. We have made significant progress advancing our MYCO-001 clinical trials for smoking cessation to date with JHU,” noted Josh Bartch, the Chief executive Officer (“CEO”) of Mydecine. “The opportunity to play an integral role in this landmark study by supplying our lead drug candidate, not only offers a significant opportunity to further advance our drug development through safer and more viable results, but demonstrates Mydecine’s leadership position in the emerging psychedelic-assisted psychotherapy industry,” he added (https://ibn.fm/GKO9v). Mydecine has expressed its optimism for the phase 2/3 trial, along with future studies on psilocybin to treat other indications in mental health and addiction, focusing on two main indications- smoking cessation and post-traumatic stress disorder (“PTSD”). The company is confident that the results from these studies will help patients dealing with such conditions and support its overall mission going forward, ultimately making MYCO-001 possibly the first psilocybin therapy to be approved for any indication. For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Research and Markets released new online gaming industry report, expecting significant growth with CAGR of 11.94% between 2021-2026
• Swedish University study suggests rapid growth in online gaming resulted from COVID-19 lockdowns
• Grand View Research report predicts online gambling market will reach $127.3 billion by 2027
• PLGNF provides multi-tenant gateway that enables online operators to offer popular games that include Live Dealer Casino, E-Table Games, and Daily Fantasy Sports
• PLGNF’s privacy-focused software enables seamless integration at operator level, allows users to access the platform without sharing sensitive data or requiring app store download

Research and Markets recently released a report titled “Online Gambling Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)” that highlights future growth prospects for the online gaming industry (https://ibn.fm/dmk2N). Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF), a SaaS technology company focused on developing and licensing digital content for the growing global iGaming industry, is positioned to take a significant share of the increasing market by offering a first-rate gaming experience while ensuring total user privacy. According to the report, long-term interest in online gaming emerged due to COVID-19 lockdowns that drove consumers online to mediate the economic, social, and psychological effects of government restrictions. Specifically, research conducted by the Lund University in Sweden suggests that the forced closure of sporting events resulted in a surge of interest in online gambling platforms. “In response to the closure of many gambling establishments, several operators went digital,” reads the summary of the report (https://ibn.fm/hqErc). “Many players expanded their online gambling offerings, and bingo operators moved their offerings online, which positively impacted the market.” Analysts at Research and Markets expect a CAGR of 11.94% between 2021-2026, with online betting leading the sector as the fastest-growing segment during the forecast period. Innovations in technology such as artificial intelligence, machine learning, and cashless payments are expected to spur industry growth, along with a growing female segment contributing substantially to the increasing user base. According to Grand View Research, the online gambling market is expected to reach $127.3 billion by 2027 (https://ibn.fm/bKb1A), with much of that growth coming from the United States and Asia. PLGNF provides an innovative multi-tenant gateway that enables online operators to offer users popular games such as Live Dealer Casino, E-Table Games, and Daily Fantasy Sports. The company’s proprietary software combines high-definition live streaming dealers with state-of-the-art augmented reality betting to provide an authentic casino experience based in Las Vegas. In addition, the company’s privacy-enhanced software enables seamless integration at the operator level while allowing users to access the platform without sharing sensitive data or requiring an app store download. PLGNF’s products are ideal turn-key solutions for online casinos, land-based operators, sportsbook operators, media groups, and big database companies. With a portfolio of IP-protected assets and high barriers to entry, the company is positioned favorably within the rapidly growing iGaming industry. For more information, visit the company’s website at www.Playgon.com. NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF

• U.S.-based mobile tech services provider FingerMotion is laser-focused on the Chinese phone consumer market, building revenues primarily from SMS and MMS services there but expanding into insurance data services with other corporate partners
• The company’s trademarked big data platform Sapientus handles over half a million transactions daily for its mobile payment and recharge services
• Analysts have noted the huge potential for upgrade services in China given consumer interest in replacing their high-end smartphones and acquiring 5G network capability
• Although there were 180 million 5G users at the end of last year, the government has promoted the fast-speed network and among 1.62 mobile phone subscriptions, 90 percent of those who replied to a Strategy Analytics survey stated they want to upgrade to a 5G phone

China’s hungry smartphone market appears poised for a very strong upgrade cycle if analysis by Strategy Analytics holds true in regard to the country’s technology buying trends. The market watch company reported on a recent survey that found 35 percent of high-end smartphone users in the Asian nation will change their phones in the next six months and that 90 percent of users want their next smartphone to be 5G-enabled, according to a subsequent review by China Internet Watch (https://ibn.fm/OcjbY). The appetite for mobile products and services among China’s 1.4 billion-person user base underscores the strength of communications technology solutions provider FingerMotion (OTCQX: FNGR) in positioning itself to deliver new value-added phone products to China’s consumers. Seeking Alpha recently noted that there were 180 million 5G subscribers as of the end of last year but 1.62 billion mobile phone subscriptions within China (thanks largely to the fact that many Chinese consumers prefer to have multiple phones), showing the potential for phone upgrades (https://ibn.fm/WeGD8). FingerMotion’s primary revenue stream has been from short and multimedia messaging (SMS and MMS) services but the company recently announced the addition of two brands partnered with a large American insurance company to provide mobile device protection program services such as coverage of broken phone screens, accidental damage repairs and compensation, and older device trade-ins (https://ibn.fm/W4lwF). The partnership is emblematic of FingerMotion’s new forays into the insurtech market by drawing on the big data capabilities of its Sapientus platform, which handles over half a million transactions daily for its mobile payment and recharge services, and using those big data resources to help insurers efficiently process claims while screening for fraud and abuse, thereby providing FingerMotion a new revenue stream in the process. FingerMotion gained the attention of global insurer Pacific Life earlier this year, inking an agreement to provide consumer risk data for Pacific Life’s Re-insurance division in China (https://ibn.fm/gLQiB). FingerMotion’s mobile device protection services are expected to launch early next year, although beta testing is already taking place this month in Shanghai, Guangdong, Anjui, Zhejiang, and Henan provinces. “This latest development demonstrates the flexibility of our business model to explore ways to monetize our vast active user base,” CEO Martin Shen stated in regard to the protection program services. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Company releases positive results from preclinical study focusing on psilocybin program CYB003
• Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare
• Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration

According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of its psilocybin programs (https://ibn.fm/mu4aT). “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin CEO Doug Drysdale. “Cybin has always strived to develop safer and more effective therapies for patients, which has guided our multiple psilocybin programs: CYB001, CYB002, and CYB003.” According to the company, positive CYB003 preclinical findings demonstrate distinctive advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. Those results “may have wide-reaching implications for the treatment of MDD, as well as alcohol use disorder (‘AUD’), with less patient variability, faster onset of action, shorter duration of effect and improved brain penetration,” the company reported. According to previous research, oral psilocybin appears to be efficacious in treating mental health disorders, especially MDD, but the treatment does have significant limitations, including slow onset of action, extended duration of effect and a variability in response among patients. Cybin’s CYB003 program is designed to maintain the benefits of oral psilocybin while addressing the challenges. Based on its multispecies, preclinical studies, Cybin has been able to do just that. The company’s CYB003 program showed faster onset of action equates to less down time in the clinic before effects begin; half the duration of effect translates to shorter clinic days or more patients per day; more predictable dose effects create a safer and more effective patient response; lowered peripheral exposure diminishes the risk of nausea; and better brain penetration suggests lower overall dose needed to achieve clinical efficacy. “While we are all encouraged by the benefits of psilocybin, we need to transparently and openly discuss its limitations if we are to translate psychedelics to therapeutics for patients in need,” said Drysdale. “The majority of current clinical studies are based on psilocybin. We have taken the necessary steps to potentially unlock the powerful benefits of psychedelics and engineer a superior molecule as demonstrated by the data. We are on a mission to make ethical, safe scientific progress to advance the care and treatment of mental health patients. Our goal has always been to be a leader in creating the best therapy for patients; today, we move one step closer.” For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• PlantX just acquitted a 53.5% stake at Eh Coffee and a 51% stake at Portfolio Coffee Inc.
• The acquisition marks PlantX’s addition of coffee to its line of over 5,000 plant-based products
• PlantX will push products from these two companies on its e-commerce platform and physical XMarket stores

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) just announced the acquisition of a majority equity interest in Eh Coffee Corp. and Portfolio Coffee Inc. for a share consideration of 913,320 PlantX shares and a cash consideration of $434,058.14. This leaves PlantX with a 53.5% and 51% stake at Eh Coffee and Portfolio, respectively. Additionally, the company now holds three out of five board seats at each company (https://ibn.fm/cBK7a). Eh Coffee and Portfolio Coffee, founded by Jacob Fortier, Victor Nucci, and Andre Dalben, have made a name for themselves as entities that offer an industry-leading farm-to-cup coffee experience. Eh Coffee, headquartered in Toronto, Ontario, sources specialty coffee beans from key family farms worldwide and custom roasts them in Canada. On the other hand, Portfolio distributes these specialty coffees featuring different flavor profiles, roasts, and regions. Its direct trade approach empowers local farmers, and its direct-to-consumer green, sustainable packaging reflects the company’s commitment to sustainability and environmental conservation. PlantX has expressed its enthusiasm with these acquisitions. They present an opportunity for the company to grow its product line, which comprises over 5,000 plant-based products. “We are delighted to welcome the Eh Coffee and Portfolio Coffee teams to the fold of the PlantX family. Coffee is perhaps the most widely accepted plant-based product- and a universal drink to start our days. We are beyond thrilled to join together our teams to launch the Portfolio Coffee offerings roasted right here in Canada for a farm to cup experience of premium specialty coffees on the PlantX website, XMarket stores and future cafes,” noted Lorne Rapkin, the Chief Executive Officer (“CEO”) of PlantX. PlantX plans to sell products from these two companies on its online platform and its physical locations. Additionally, featuring the Portfolio brand at the XMarket Cafes will allow PlantX to offer same-day delivery within Tel Aviv, Toronto, Ottawa, Los Angeles, San Diego, and Vancouver. The company also plans to leverage its e-commerce knowledge and distribution experience to bring Portfolio’s e-commerce subscription to new heights. Eh Coffee and Portfolio’s existing management teams will remain involved in day-to-day operations and the companies’ business going forward. The addition of the founders to PlantX’s top-level management adds to its human resource’s wealth of experience and industry know-how. Portfolio, alone, for instance, has an executive team with over 20 years of experience working with award-winning farms through the global coffee supply chain, roasting and retailing specialty coffees. “We are very excited to join the PlantX team and bring the joys of coffee drinking and connoisseurship to XMarket stores and PlantX consumers. We believe that curated farm-to-cup specialty coffee from renowned crop growing regions is the sustainable path of the future for specialty coffee,” noted Eh Coffee and Portfolio founders collectively. The purchase agreement for the Eh Coffee and Portfolio acquisition provides that PlantX will have the option to purchase up to all the remaining shares on the two companies over the course of three calendar years following the closing of the transaction. All the PlantX shares issued thus far and to be issued in connection to the transaction are expected to be, upon issuance, subject to a restrictive hold period of four months and one day. PlantX hopes this new chapter of growth will add to its value, market reach, and overall brand equity. In addition, this move aligns with PlantX’s expansion strategy, particularly since the company also has plans to include cosmetics, clothing, and its own water brand. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions
• The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets
• The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery platform
• Lexaria will also be conducting pharmacokinetic and efficacy modeling studies in animals to evaluate DehydraTECH’s overall efficiency

In 2021, Lexaria Bioscience (NASDAQ: LEXX) raised approximately $15 million in funding. The money allowed for active work programs throughout the year while supporting significant advances in oral nicotine, heart disease, and antiviral research. Lexaria plans to take the findings from these 2021 studies and improve them with the 2022 R&D programs, which include hormone replacement, dementia, diabetes, and rheumatoid disease (https://ibn.fm/8H7tm). While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, noted, “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension, and separately, for oral nicotine delivery as an alternative to smoking.” “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added. Lexaria announced a fraction of their 2022 applied R&D programs, among them HOR-A22-1, DEM-A22-1, RHEUM-A22-1, and DIAB-A22-1. HOR-A22-1, slated for April 2022, will be a hormone replacement study. It will evaluate the ability of Lexaria’s patented DehydraTECH to enhance estrogen among patients, allowing for the control of the menstrual cycle, cholesterol, and the protection of bone health. Through this study, Lexaria plans to capitalize on the hormone replacement market, which is estimated to grow to $46.5 billion by 2027. DEM-A22-1, scheduled for July 2022, will explore the efficiency of DehydraTECH-CBD, with and without nicotine, for the potential treatment of dementia. Once again, Lexaria plans to capitalize on the dementia drug market, which is estimated to grow to $19.6 billion by 2026. RHEUM-A22-1, scheduled for October 2022, will focus on rheumatoid disease treatment through the use of DehydraTECH-CBD. Through this study, Lexaria intends to take advantage of the growing Rheumatoid Arthritis Therapeutics market, which is projected to be valued at $30 billion by 2025. DIAB-A22-1, which is slated for November 2022, will evaluate the ability of DehydraTECH-CBD to potentially affect the treatment of diabetes. Studies so far have shown that CBD can reduce the incidence of diabetes in mice, a significant milestone in the study. Improving on these findings, Lexaria is strategically evaluating the prescription drug market used to treat diabetes, an industry expected to be valued at $77.9 billion by 2024. In addition to these studies, Lexaria also announced that it would be conducting pharmacokinetic (“PK”) and efficacy modeling studies in animals to evaluate DehydraTECH’s ability to improve the delivery characteristics of various other drugs or active pharmaceutical ingredients (“APIs”). The goal would be to identify whether there could be a commercial benefit to continue further studies and pursuit within different market sectors. Lexaria has been vocal about its R&D initiatives and endeavors. Additionally, it has remained true to its objective to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health. The 2022 work programs are the company’s next biggest undertakings, and they stay true to what it stands for, along with its commitment to its stakeholders. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028
• The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth
• Nemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives

According to a recent Reports and Data release, the global consumer monitoring (“CGM”) devices global market is forecast to see notable growth in the coming years (https://ibn.fm/LhWNO). Key companies operating in the space, including Nemaura Medical (NASDAQ: NMRD), are ideally positioned to benefit from that growth as they work to meet the needs of the industry. The increasing prevalence of diabetes and rising focus on preventive care are major factors in the steady revenue growth projected for the CGM devices market, according to the latest analysis by Reports and Data. “The global continuous glucose monitoring devices market size was USD 4.11 billion in 2020 and is expected to reach USD 19.04 billion in 2028 and register a revenue CAGR of 19.2% during the forecast period, 2021–2028,” the article stated. “Continuous glucose monitoring devices enables tracking of blood glucose levels round the clock,” the article continued. “These devices monitor a patient’s glucose levels via sensors that send readings to the receiver’s device screen or smartphone. Continuous glucose monitoring devices aid patients in managing diabetes with lesser fingerstick tests. Increasing prevalence of diabetes in countries across the globe and growing preference for monitoring and managing diabetes at home are boosting adoption of continuous glucose monitoring devices. In addition, rapid technological advancements in glucose monitoring devices and increasing affordability of innovative devices are some other factors expected to contribute to revenue growth of the market going ahead.” The report also noted that wearable CGM devices can help patients track and understand how their sugar levels change over time. The devices also provide alerts when glucose levels reach levels fall below or rise above acceptable levels. In addition, “CGM data can provide healthcare providers critical insights into patterns of high and low glucose levels, in turn, leading to a personalized care approach and better management of diabetes. These advantages are further boosting adoption of these devices and are expected to fuel revenue growth of the market over the forecast period.” Nemaura Medical’s proprietary sugarBEAT(R) device is the world’s first-of-its-kind noninvasive continuous glucose monitoring sensor designed for use by “everyone,” meaning people dealing with either type 1 or type 2 diabetes as well as those with prediabetes. The device attaches on (not under) the skin and measures real-time blood glucose levels every five minutes. Using that data, users can track their highs and lows, identify trends, and monitor their Time in Range (TIR). This invaluable information allows individuals to make adjustments to their diet and activity that can significantly change their lives. Nemaura Medical evolved from a micro-system-based drug-delivery platform in 2011. Since then, the company has developed a platform to monitor multiple chemicals in the blood without needles, replacing traditional invasive methods of diagnosis and healthcare observation procedures. Nemaura’s BEAT(R) technology allows for continuous remote monitoring of chronic diseases and health conditions. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• HENC subsidiary evaluating, pursuing property acquisitions; beginning process to obtain cultivation, sales licenses
• Sales have doubled in the past year, according to state’s seed-to-sale tracking system
• HENC working with top cannabis law firm to spearhead the process

With Massachusetts reporting marijuana sales reaching $2 billion since the state approved the adult-use market (https://ibn.fm/S8IvV), savvy cannabis companies operating in the state are looking to leverage opportunity for growth. Earlier this year, Hero Technologies (OTC: HENC), a cannabis company pursuing a vertically integrated model, announced a new subsidiary: MassCannabis LLC. The newly formed company is evaluating and pursuing property acquisitions and beginning the process to obtain licenses in Massachusetts (https://ibn.fm/XpF9F). The Cannabis Control Commission in Massachusetts has reported that gross sales from the state’s 165 cannabis retailers and three delivery services reached $2,009,007,478 as of August 31, 2021. “That doubles the sales total that the commission reported last November, according to the state’s seed-to-sale tracking system,” the report noted. “This milestone speaks to the success of licensees that have interacted with the Commission from the application stage, maintained compliance with our strict regulations, and contribute every day to communities across the Commonwealth.” In March 2021, HENC announced that it had retained a top cannabis law firm, Vincente Sederberg LLP, “to spearhead the process to obtain cannabis licenses in Massachusetts, a rapidly growing cannabis market with over $1 billion in retail sales since 2019. Vincente Sederberg is a leading advocate for the cannabis industry, with over a decade of experience in cannabis law,” the company stated. “Rolling Stone” magazine has called Vincente Sederberg a “powerhouse marijuana law firm.” “Hero Technologies’ newly formed subsidiary, MassCannabis LLC, will work closely with Sederberg to target property acquisitions and begin the process to obtain licenses to cultivate and retail cannabis in Massachusetts,” the company noted. “We are very excited about our momentum in Massachusetts,” said Hero Technologies CEO Gina Serkasevich. “Having Vincente Sederberg join forces with our new MassCannabis subsidiary should enable us to quickly identify new strategic partners and streamline the acquisition process. We look forward to reporting more developments to our shareholders as we continue to expand and integrate cannabis initiatives across geographical markets.” For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• SRAX will publish its third quarter quarterly results on Monday 15th November
• The company will also hold an investor earnings call alongside the results release, led by SRAX CEO, Christopher Miglino and CFO, Michael Malone
• Following their second quarter results, the company upped its 3Q revenue guidance to $8.3 million, representing a +7.7% quarter-on-quarter crisis
• SRAX have also recently revealed their attendance at the Ladenburg Thalmann Virtual Technology Expo, which will be held on their Sequire platform on November 18th, 2021

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has revealed that it will publish its third quarter 2021 results on Monday, November 15th (https://ibn.fm/gLEuN). On the day, SRAX’s Founder and CEO, Christopher Miglino, and CFO, Michael Malone, will provide an operational and financial summary of Q3 2021 on a video call, featuring a live question and answer session, to be held at 4:30 pm ET / 1:30pm PT. To register for the live webcast and view the presentation, investors will be able to sign up at the following link: (https://ibn.fm/BH6i4). SRAX has seen its financial returns enjoy a remarkable rise over the past year. For the second quarter of fiscal 2021, the company reported Q2 revenues of $7.7 million, up 557% year-over-year, and rising by 41% quarter-on-quarter. The company also seized on the opportunity to update their corporate revenue guidance, increasing Q3 revenue guidance to $8.3 million, which would represent at least a +7.7% quarter-on-quarter increase. SRAX also increased their full year revenue target to $32 million, up from $30 million previously (https://ibn.fm/uWMli). Immediately following their second quarter earnings report, SRAX announced that they would be carrying out a simultaneous $10 million stock buy-back program as well as paying a one-time special dividend to its shareholders of records as of the 20th of September 2021. The special dividend, which would bear an approximate value of $0.23 per common share, would be in the form of an issuance of non-tradeable preferred shares, which would hold a notional value of approximately $6.5 million worth of Sequire’s clients’ stock. As the underlying shares are sold, the proceeds will be distributed to the preferred shareholders on a periodic basis. In addition to their upcoming quarterly earnings results announcement, SRAX has also recently announced that the company will be presenting at the Ladenburg Thalmann Virtual Technology Expo, a one-day investor event featuring major technology companies, on November 18th. The event, which is being hosted on the Sequire virtual conferencing platform, will feature presentations from the management of approximately 50 technology companies from the US and Israel, covering a diverse array of sectors, including connectivity, cloud and enterprise software, cybersecurity, streaming, semiconductors and cryptocurrencies, among a variety of others (https://ibn.fm/9s0F0). For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• The VBF acquisition is expected to be accretive to MCOA’s revenue and EBITDA forecasts for 2022
• The company launched new subsidiaries in Brazil and Uruguay to distribute its hempsmart premium product line in Latin America
• The company recently launched a new social media marketing campaign via Instagram, Twitter, TikTok, etc.
• The global legal marijuana market was valued at $9.1 billion in 2020 and is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028, putting the market value at roughly $30 billion by 2025

Marijuana Company of America (OTC: MCOA) operates and invests in the cannabis sector directly. The company’s diverse operations include cDistro, one of the THC, hemp & CBD cannabis industries’ fastest growing distribution companies; hempsmart(TM), a premium CBD company; and VBF Brands Inc., a cannabis nursery cultivation facility in Salinas, California, that is a cultivator and distributor utilizing its own growing systems to produce desirable cannabis clones. MCOA continues to grow its business while remaining fiscally conscious and further establishing itself in the legalized cannabis THC, hemp & CBD industries by offering unique exposure to the global cannabidiol sector. The company intends to continue to leverage its premium brand hemp-based products with investments in and collaboration with existing and new strategic partners. Marijuana Company of America offers investors the opportunity to be at the forefront of innovation in the legal cannabis and industrial hemp industries. During the summer of 2021, the U.S. witnessed the introduction of the most comprehensive cannabis reform ever proposed at the federal level, as well as ongoing state-level liberalization. The investments MCOA has made will position the company to drive the expected strongest revenue growth in the company’s history. MCOA strives to develop a comprehensive selection of synergistic companies that provides consistent value to its shareholders. Furthermore, its vertically integrated business model provides companies and partners with the best opportunities for rapid growth. It is MCOA’s attention to detail in producing premium products and adhering to the best business practices that distinguish it among the leaders of cannabis products in the global marketplace. MCOA is building a portfolio of investments and joint ventures that represent the highest integrity and professionalism in the legal cannabis and industrial hemp markets. MCOA is a model for entrepreneurs and businesses that share its common goals and philosophies of not only creating value for investors but also creating an environment for businesses to improve the quality of life of customers through sustainable alternatives to many products currently on the market. Partnerships and Investments MCOA has partnered with and invested in a portfolio of companies operating in the cannabis sector. These include: Cannabis Global Inc. Cannabis Global (OTC: CBGL) is an emerging force in the cannabis marketplace with growing product and intellectual property portfolios. CBGL is marketing and producing Comply Bag(TM), an innovative solution for cannabis storage, transport, and tracking, and is also the developer and marketer of the Hemp You Can Feel(TM) brand. Eco Innovation Group Inc. Eco Innovation Group (OTC: ECOX) works with inventors and other professionals to nurture and catalyze the most innovative and impactful products and services and deliver those innovations to market. ECOX is dedicated to developing and commercializing successful products. MCOA’s investment supports Eco Innovation’s cutting-edge extraction technology. ECOX’s extraction processes utilize a proprietary formulation to extract valuable bioactive compounds from cannabidiol (“CBD”) combined with plant-based materials to create a fluid and cost-effective output. Together, both companies are positioned to identify and accelerate the development of new varieties of hemp-based products and distribute them worldwide. Natural Plant Extract MCOA owns a direct investment interest in Natural Plant Extract (“NPE”), which operates a licensed cannabis manufacturing and distribution business in Lynwood, California. NPE holds a Type 7 California manufacturing and distribution license, allowing for cannabis product distribution anywhere in the State of California. Wholly Owned Subsidiaries hempsmart(TM) hempsmart(TM) is a CBD company focused on creating and promoting the most effective, best tasting, and highest quality products on the market. In 2021, hempsmart expanded into the global marketplace and announced a rebrand that featured a fresh take on its packaging and a social media campaign to engage customers via Instagram, Twitter, TikTok, and more, which has now generated a new loyal group of followers. hempsmart premier products include its Smart Drops (CBD Drops), Neuro Smart (Patented Brain Pills), and Smart Cream (Pain Cream) brands. These organic, plant-based products help to manage anxiety, pain and insomnia, without the inclusion of THC. cDistro cDistro distributes CBD brands, along with smoke and vape shop-related products, to wholesalers, c-stores, specialty retailers, and consumers in North America. cDistro was chosen as one of the first to distribute Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family. The initial product offering will include a range of functional mushroom tinctures, including species such as cordyceps, lion’s mane, chaga, reishi and turkey tail, that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement. VBF Brands Inc. MCOA recently completed the acquisition of VBF Brands Inc., a fully licensed marijuana cultivator and distributor based in Salinas, California. VBF utilizes its own growing systems to produce desirable cannabis clones that are designed to assist growers by reducing uncertainty and enhancing the likelihood of a successful cultivation harvest. Cannabis clones carry the exact same genetic potential as their mother plants and have similar cannabinoid and terpene profiles when grown properly. This subsidiary will immediately work toward increasing production at its Salinas facility, which also offers exponential growth potential with other nearby properties that MCOA has an option to participate in as part of the acquisition. Market Outlook Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will increase opportunities for this market. According to a Grand View Research report, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028. That would put the market value at roughly $30 billion by 2025. The report cites the growing number of countries that are legalizing cannabis as a driver for surging demand. It also points out the use of medical marijuana for various ailments is gaining momentum worldwide. Medical marijuana is prescribed for patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s and other neurological disorders. The demand for cannabis oil is also increasing rapidly, especially among countries with legalized medical marijuana. Management Team Jesus Quintero is the CEO and Chairman of MCOA. From January 2013 to September 2014, he was the Chief Financial Officer of Brazil Interactive Media Inc. Since 2011, he has served as a financial consultant to several multimillion-dollar businesses in South Florida. He has extensive experience in public company reporting and SEC/SOX compliance and held senior finance positions with Avnet Inc., Latin Node Inc., Globetel Communications Corp., and Telefonica of Spain. His prior experience also includes positions at Price Waterhouse and Deloitte & Touche. He holds a B.S. in Accounting from St. John’s University and is a certified public accountant. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com. NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA